STAT3 and epithelioid sarcoma: Another small molecule inhibitor, LY5, which inhibits homodimerization by blocking the phosphotyrosine site of the STAT3 SH2 domain, inhibited STAT3 activation by decreasing the cell viability of sarcomas, including osteosarcoma, ES, and RMS.